Is Trident Texofab Ltd debt-free?

No, Trident Texofab Ltd is not debt-free with a debt-to-equity ratio of 0.63.

Home

Trident Texofab Ltd

Trident Texofab Ltd Financials

Trident Texofab Ltd Financial Statement

Trident Texofab Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Jun 2025	Mar 2025	Dec 2024
Revenue	28.52	38.68	31.49
Operating Expense	26.01	36.90	29.37
Net Profit	1.02	0.51	0.30
Net Profit Margin	3.58	1.32	0.95
Earning Per Share	0.72	0.50	0.30
EBIDTA	2.44	2.06	2.16
Effective Tax Rate	11.20	8.43	3.30

Particulars	Jun 2025
Revenue	28.52
Operating Expense	26.01
Net Profit	1.02
Net Profit Margin	3.58
Earning Per Share	0.72
EBIDTA	2.44
Effective Tax Rate	11.20

Trident Texofab Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Total Revenue Annual	122.06	99.48	96.36
Operating Expenses Annual	116.58	93.33	90.05
Operating Profit Annual	8.77	6.85	8.08
Interest Annual	4.55	4.04	3.71
Depreciation	1.52	1.52	1.51
Net Profit Annual	2.51	1.08	2.22
Tax Annual	0.07	0.09	0.51

Particulars	Mar 2025
Total Revenue Annual	122.06
Operating Expenses Annual	116.58
Operating Profit Annual	8.77
Interest Annual	4.55
Depreciation	1.52
Net Profit Annual	2.51
Tax Annual	0.07

Trident Texofab Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Cash Flow at the Beginning	0.16	0.06	0.04
Cash Flow from Operations	-13.72	2.71	5.85
Cash Flow from Investing	-19.92	-0.57	0.37
Cash Flow from Financing	36.65	-2.05	-6.20
Cash Flow at the End	3.16	0.16	0.06

Particulars	Mar 2025
Cash Flow at the Beginning	0.16
Cash Flow from Operations	-13.72
Cash Flow from Investing	-19.92
Cash Flow from Financing	36.65
Cash Flow at the End	3.16

Trident Texofab Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
PBDIT Margin (%)	6.84	8.33	10.36
PBIT Margin (%)	5.49	6.67	8.66
PBT Margin (%)	4.64	5.51	7.11
Net PROFIT Margin (%)	2.06	1.09	2.30
Return On Networth / Equity (%)	2.61	5.47	15.78
Return On Networth /Employed (%)	9.82	11.75	15.10
Return On Assets (%)	3.68	1.91	4.01
Total Debt / Equity (X)	1.10	2.48	2.72
Asset Turnover Ratio (%)	1.79	1.76	1.74

Particulars	Mar 2025
PBDIT Margin (%)	6.84
PBIT Margin (%)	5.49
PBT Margin (%)	4.64
Net PROFIT Margin (%)	2.06
Return On Networth / Equity (%)	2.61
Return On Networth /Employed (%)	9.82
Return On Assets (%)	3.68
Total Debt / Equity (X)	1.10
Asset Turnover Ratio (%)	1.79

Trident Texofab Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Fixed Assets Annual	20.09	21.73	23.33
Total Current Assets Annual	73.74	52.10	46.69
Non Current Assets Annual	26.83	29.79	30.62
Total Shareholders Funds Annual	47.24	16.26	15.18
Total Assets Annual	100.58	81.90	77.31

Particulars	Mar 2025
Fixed Assets Annual	20.09
Total Current Assets Annual	73.74
Non Current Assets Annual	26.83
Total Shareholders Funds Annual	47.24
Total Assets Annual	100.58

Trident Texofab Ltd Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

FAQS on Trident Texofab Ltd Financials

As of Oct 26, 2025, Trident Texofab Ltd has a market capitalization of 237.01 Cr. Value Research classifies it as a Small-Cap company.

Yes, Trident Texofab Ltd is not with a debt-to-equity ratio of 0.63.

In FY 2024 , Trident Texofab Ltd recorded a total revenue of approximately 122.06 Cr marking a significant milestone in the company's financial performance.

Trident Texofab Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.7% and 0.1% annually, respectively..

Trident Texofab Ltd's current PE ratio is 94.43.

Trident Texofab Ltd's ROCE averaged 9.7% from the FY ending March 2023 to 2025, with a median of 9.1%. It peaked at 11.7% in March 2023, reflecting strong capital efficiency over the period..

Trident Texofab Ltd's latest EBIT is Rs. 7.13 Cr, surpassing the average EBIT of Rs. 6.26 Cr over the 5 years..